Enanta Pharmaceuticals (NASDAQ:ENTA) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Enanta Pharmaceuticals has been assigned a "sell (D-)" rating by Weiss Ratings, indicating a negative outlook for the company's stock.
• Despite some analysts issuing buy ratings, the stock has a consensus average rating of "Moderate Buy" with a price target of $20.83, far above its current trading price of $10.51.
• The company's recent earnings report showed a loss of ($0.85) per share, which was better than analysts' expectations, alongside revenues surpassing their consensus estimate.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

A number of other analysts also recently issued reports on the stock. Westpark Capital increased their target price on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a research report on Tuesday, September 30th. Jefferies Financial Group upgraded Enanta Pharmaceuticals from a "hold" rating to a "buy" rating and upped their price target for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. HC Wainwright began coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a "buy" rating and a $20.00 price target for the company. JMP Securities upped their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 12th. Finally, Evercore ISI decreased their price target on Enanta Pharmaceuticals from $20.00 to $12.00 and set an "outperform" rating for the company in a report on Monday, September 15th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $20.83.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $10.51 on Friday. The firm has a 50 day moving average price of $9.48 and a 200 day moving average price of $7.56. The company has a market cap of $224.68 million, a PE ratio of -2.43 and a beta of 0.89. Enanta Pharmaceuticals has a 1 year low of $4.09 and a 1 year high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.25) by $0.40. The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. On average, sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at approximately $36,000. Farther Finance Advisors LLC boosted its stake in shares of Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock valued at $44,000 after buying an additional 5,779 shares during the last quarter. MetLife Investment Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at approximately $72,000. Corton Capital Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at approximately $77,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $88,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.